Antibiotic Resistance Market
Antimicrobial resistance occurs when microorganisms such as bacteria, viruses, fungi, and parasites change when they are exposed to antimicrobial drugs. Antibiotic drugs include antibiotics, antifungals, antivirals, antimalarials, and anthelmintic.
Antibiotic Resistance Market is expected to reach USD 17387.01 million at CAGR of 5.34% during the forecast period of 2020 to 2030
Antibiotic Resistance Market Overview Analysis by Drug Class (Oxazolidinones, Lipoglycopeptides, Tetracyclines, Cephalosporins, Combination Therapies and others), Disease (Complicated Urinary Tract Infection (cUTI), Blood Stream Infections (BDS), Complicated Intra-Abdominal Infections (cIAI), Clostridium Difficile Infections (CDI), Acute Bacterial Skin and Skin Structure Infections (ABSSSI), Hospital-Acquired Bacterial Pneumonia/Ventilator (HABP/VABP), Community-Acquired Bacterial Pneumonia (CABP), Others), Pathogen (Staphylococcus Aureus.
The growth of global antibiotic resistance market is driven by various factors such as - Rising antibiotic drug resistance infections, rise in the incidence of chronic and infectious disease, increase in clinical developments of antibiotic resistance, and rise in global initiatives to control drug-resistance
Several market players currently dominate the global antibiotic resistance market. The key players are involved in product launches and strategic collaborations to strengthen their market positions.
Major Key Players:
Some of the Key Players are Achaogen, Inc. (US), MELINTA THERAPEUTICS, INC. (US), Nabriva Therapeutics plc (Ireland), PARATEK therapeutics (US), Seres Therapeutics (US), Theravance Biopharma (UK), Tetraphase Pharmaceuticals (US), Basilea Pharmaceutica Ltd. (Switzerland), Entasis Therapeutics (US), NEMESIS BIOSCIENCE LTD (UK), Procarta Biosystems (England), and Allecra Therapeutics (US)
Segment Analysis
The Global Antibiotic Resistance Market Research Report by Drug Class, Disease, Pathogen, and End User.
The market, based on drug class, has been divided into cephalosporins, Combination therapies, tetracyclines, lipoglycopeptides, oxazolidinones, and others. The combination therapies segment is likely to be the largest growth during the review period due to the increased usage of these therapies for gram-negative infections. Additionally, it has minimal treatment options available with the increasing demand for antibiotic resistance, thus driving the growth of this segment.
The global antibiotic resistance market has been bifurcated, based on disease, into complicated urinary tract infections, bloodstream infections, complicated intra-abdominal infections, clostridium difficile infections, acute bacterial and skin structure infections, hospital-acquired bacterial pneumonia/ventilator, community-acquired bacterial pneumonia, and others. The complicated urinary tract infections segment is expected to hold the majority share of the market as urinary tract infections (UTIs) are one of the most common types of infections. Additionally, there were around 1,045 patients affected by UTI.
The global antibiotic resistance market has been segmented based on pathogen into staphylococcus aureus, streptococcus pneumoniae, antibiotic resistant bacteria, acinetobacter, enterococcus, Hemophilus influenzae, pseudomonas aeruginosa, clostridium difficile, K. pneumoniae, campylobacter, and others. K. pneumoniae is expected to be the fastest segment owing to the increasing K. pneumoniae. Moreover, there were around 212,500 infection cases per year and about 70 deaths every year which would eventually drive the growth of the antibiotic market in this segment.
The end user segment of the antibiotic resistance market includes hospitals clinics, research organizations, and others. The hospitals clinics segment is expected to hold the largest share of the market as the majority of treatments and procedures are carried out in hospitals, which ultimately increases the usage of antibiotic resistance drugs in the antibiotic resistance market. As a result, this drives the growth of the antibiotic resistance market.
Regional Analysis
The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East Africa. The Americas is expected to be the largest market owing to the rising growth in the pharmaceutical sector. The antibiotic resistance market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European antibiotic resistance market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The antibiotic resistance market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Increasing healthcare expenditure has boosted the growth of the antibiotic resistance market; the market in Asia-Pacific is expected to be the fastest-growing. The antibiotic resistance market in the Middle East Africa has been divided into the Middle East and Africa.
About Market Research Future
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
In order to stay updated with technology and work process of the industry, MRFR often plans conducts meet with the industry experts and industrial visits for its research analyst members.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 646 845 9312
